Currently, only a subset of patients with chronic myeloid leukemia (CML) pursuing treatment-free remission (TFR) enjoy success. At the 64th ASH Ann......READ MORE
At theĀ 64th ASH Annual Meeting and Exposition, researchers continued to explore new ways to optimize the treatment of chronic phase chronic myeloid......READ MORE
Although great progress has been made in the treatment of chronic phase chronic myeloid leukemia (CML), many patients still experience intolerance ......READ MORE
At the 64th ASH Annual Meeting and Exposition, emerging data underscored the importance of tyrosine kinase inhibitor (TKI) tolerability and dose op......READ MORE
The treatment of chronic phase chronic myeloid leukemia (CML) is evolving in response to newer data on BCR::ABL1 tyrosine kinase inhibitors (TKIs).......READ MORE
At the 64th ASH Annual Meeting and Exposition, emerging data on the treatment of chronic phase chronic myeloid leukemia (CML) continued to add to t......READ MORE